Enveric Biosciences tightens communications with centralized portal and mandatory pre-release checklist

Enveric tightens communication protocols after incomplete posting

Enveric Biosciences is updating its media and investor communications processes after a recent incident in which an external request for an article was submitted with only the word "Gainers," creating confusion among recipients. The clinical-stage developer of psychedelic-based therapeutics says it is instituting a centralized submission portal, a mandatory pre-release checklist and an internal review team to screen outbound materials. The company frames the move as an effort to protect scientific integrity and reduce the risk of miscommunication around clinical updates and regulatory disclosures.

New submission portal aims to prevent incomplete disclosures

Enveric is rolling out the portal within days and is training communications and clinical staff on standardized templates and verification procedures. The system enforces required fields, attaches a log of clarifying questions and routes documents to a compliance reviewer before publication or investor distribution. Company spokespeople say the change is designed to shorten turnaround for legitimate information requests while avoiding partial or placeholder releases that can generate uncertainty among partners, investigators and patient communities.

The company emphasizes that the measures are not meant to restrict transparency but to improve accuracy of scientific and operational messaging. Enveric’s compliance lead states the initiative aligns communications with the company’s clinical protocols and data governance, reducing the risk of inadvertent release of incomplete study details. The portal also includes an audit trail to document who submits, reviews and approves materials, which the company says is useful for internal quality control and external inquiries.

Operational and pipeline context

Enveric continues to advance its research programs in psychedelic-based therapeutics and says the communications upgrade will support clearer dissemination of clinical milestones, investigator updates and collaboration announcements. Management notes that reliable, timely communication is important for recruitment sites and research partners that depend on precise protocol and safety information.

Stakeholder response and next steps

The company invites collaborators and media to use the new portal and to respond to a short set of clarifying questions when submitting text, mirroring guidance seen in recent external requests. Enveric plans to monitor the process and publish a brief report on its effectiveness in the coming weeks.